Pharma Equity Group Income Statement

Financials in millions DKK. Fiscal year is January - December.

Millions DKK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	12.05	12.29	11.81	5.78
Research & Development	5.12	9	8.82	5.5
Operating Expenses	25.29	37.48	25.03	11.28
Operating Income	-25.29	-37.48	-25.03	-11.28
Interest Expense	-2.55	-4.96	-1.56	-0.02
Interest & Investment Income	0.01	0.01	0.01	-
Currency Exchange Gain (Loss)	0	-0	-	-
Other Non Operating Income (Expenses)	1.42	-0	-	-
Pretax Income	-26.42	-42.43	-26.58	-11.3
Income Tax Expense	-1.03	-1.82	-2.23	-1.86
Net Income	-25.38	-40.61	-24.35	-9.44
Net Income to Common	-25.38	-40.61	-24.35	-9.44
Shares Outstanding (Basic)	1,228	1,068	1,080	954
Shares Outstanding (Diluted)	1,228	1,077	1,089	977
Shares Change (YoY)	14.02%	-1.10%	11.38%	-
EPS (Basic)	-0.02	-0.04	-0.02	-0.01
EPS (Diluted)	-0.02	-0.04	-0.02	-0.01
Free Cash Flow	-17.66	-22.86	-16.7	-8.3
Free Cash Flow Per Share	-0.01	-0.02	-0.01	-0.01
EBITDA	-25.26	-37.46	-25.01	-11.02
D&A For EBITDA	0.03	0.02	0.02	0.26
EBIT	-25.29	-37.48	-25.03	-11.28

Source: S&P Global Market Intelligence. Standard template. Financial Sources.